Biomarkers of relapse and therapeutic response in addictions and mood disorders

Leader

Research center

4 avenue de l'Observatoire
75006 Paris

Institution

Inserm
Université Paris Descartes
Université Paris Diderot
ED 436

Laboratory

Variabilité de réponses aux psychotropes
Phone: 01.53.73.96.34
Fax: 01.40.51.75.60
UMRS 1144

Keywords

addiction
Mood disorders
Neuropsychophamarcology
Genomics
Biomarkers
 

Publications

Geoffroy PA# , Scott J, Boudebesse C, Lajnef M, Henry C, Leboyer M, Bellivier F# , Etain B. Sleep in patients with remitted bipolar disorders: a meta-analysis of actigraphy studies. Acta Psychiatr Scand. 2014 28.

Bellivier F#, Geoffroy PA#, Etain B, Scott J. Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert Opin Ther Targets. 2015 Mar 2:1-17.

Boudebesse C, Geoffroy PA# , Henry C, Germain A, Scott J, Lajnef M, Leboyer M, Bellivier F# , Etain B. Eur Psychiatry. 2014 4.

Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Declèves X, Bergmann JF, Scherrmann JM, Laplanche JL#, Lepine JP#, Vorspan F#. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. in press

Geoffroy PA# , Boudebesse C, Henrion A, Jamain S, Henry C, Leboyer M, Bellivier F# , Etain B. An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes Brain Behav. 2014 13(3):299-304.

Fields of research

Neurological and psychiatric diseases

Research Theme

The "Biomarkers of relapse and therapeutic response in addictions and mood disorders" team develops research on mood disordersand addiction both at the clinical and fundamental level (ranked A, AERES 2013, creation 01/01/2014).The objective is to identifyclinical, biological, genetic or imaging-based markers of the response to psychotropic drugs (in the context of drug abuse or during thetreatment for mood disorders or pain management). These markers will allow us to better predict the response (therapeutic and sideeffects) in order to improve the therapeutic monitoring of patients. This research program also explores the mechanisms of action ofpsychotropic drugs.

Specifically, the candidate team “Biomarkers of relapse and therapeutic response in addiction and mood disorders” develops researchprograms on biomarkers of response to psychotropic drugs and relapse in addictions (opiates, cocaine) and bipolar disorders.Patients are recruited through its specialized centers for drug addiction and bipolar disorder at Fernand Widal Hospital (Affiliated tothe FondaMental foundation).

Several arguments justify the project of the team:
- Our past involvement in these topics and the existing cohorts that allow us to schedule ambitious research programs- The heuristic interest to address these issues with the same tools in two related but distinct clinical situations- Addictions and bipolar disorders share common characteristics such as high variability and unpredictable treatment response with amajor impact on clinical management- Addictions and affective disorders are leading causes of chronic disability, mortality and cost

The team develops two main themes:

THEME 1: PSYCHOTROPIC DRUGS RESPONSE VARIABILITY AND IDENTIFICATION OF PREDICTIVE BIOMARKERS

This theme includes the study of methadone response in opiate addict patients and lithium response in BPAD. The first aim of thisprogram is to contribute in each of these fields by identifying biomarkers predictive of this important inter-individual variability ofrelapse and response to treatment. This represents major issues for both the development of personalized medicine in psychiatry anda contribution to the exploration of specific and common etiopathogenic mechanisms of addiction and bipolar disorder. Severalongoing projects are currently funded (3 PHRC, 1 ANR générique, 1 USPC grant and the 2013 M. Dassault Research prize).

THEME 2: PREDICTIVE BIOMARKERS OF RELAPSE IN ADDICTION AND BIPOLAR DISORDERS

Relapse prevention is the main issue in the clinical management of patients with addictions. The same difficulty is observed in themanagement of bipolar patients due to a very high relapse rate despite an initial response to treatment (on average at least 50% ofrelapse 2 years after an episode). Therefore, the second axis of the research team is focused on the characterization of biomarkerspredictive of relapse. This may help to identify warning characteristics to define at-risk subgroups and new relapse preventionstrategies. Two ongoing research projects have been funded on this theme (2 PHRC).

The tools we use include molecular genetic, cell biology, brain imaging, neurocognitive assessment and phenotypic dissectioncandidate symptoms or endophenotypes in our collection of patients, relatives and control subjects.



Team members

Marie-Claire CYNTHIA
Jean-Louis LAPLANCHE
Jean-Pierre LEPINE
Emmanuel CURIS
Florence VORSPAN
Vanessa BLOCH
Frank QUESTEL
Sarah SPORTICHE
Gaël DUPUY